Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment
1. Novo Nordisk announced positive Phase 3 trial results for cagrilintide. 2. Participants lost an average of 27.6 pounds over 68 weeks. 3. Cagrilintide targets overweight adults, not diabetics, as a new treatment. 4. Shares of Novo Nordisk gained 2% but are down over 30% year-to-date. 5. The company aims to regain market share lost to competitors.